- Analgesic
- Artificial Digestive Enzyme
- Protein Supplements
- Steroids
- Antibiotics
- Others
Chronic Pancreatitis Market was valued at USD 8.2 billion in 2023 and is poised to grow at a CAGR of 5.7% over 2024-2030. Chronic Pancreatitis is a long-standing inflammation of the pancreas that alters the organ’s normal structure and functions, has symptoms such as upper abdominal pain, nausea and vomiting, steatorrhea, weight loss, and diabetes type I, and the causes of the disease include alcoholism, autoimmune disorders, intraductal obstruction, idiopathic pancreatitis, tumors, ischemia, and others. According to the Global Burden of Disease (2017), the global estimation of incidence and mortality was 9.62 cases per 1,00,000 person-years and 0.09 deaths per 1,00,000 person-years, respectively for chronic pancreatitis. An increase in consumption of alcohol and a rise in unhealthy lifestyles will act as the growth drivers for the market. However, the high cost of treatment will have a restraining impact on the chronic pancreatitis market growth. Technological advancements and increasing healthcare expenditure are the opportunities for market expansion.
Chronic Pancreatitis Market Key Developments:
- In Dec 2021, Kangen Pharmaceuticals completed a phase-I/II trial in pancreatitis in the USA, for NI-03.
- In July 2023, First Wave BioPharma announced its intention to submit BLA for Adrulipase alfa to the US FDA for exocrine pancreatic insufficiency.
Chronic Pancreatitis Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
5.7%
Largest Market
North America
Fastest Growing Market
Asia Pacific
Chronic Pancreatitis Market Dynamics
The increase in government initiatives and investments in R&D activities by the pharmaceutical companies for drug development are the major factors driving the market growth. For instance, in Aug 2020, CT Pharmaceutical Solutions held a meeting to add chronic pancreatitis condition to the Medical Marijuana Program for adults and for patients under 18 “whose pain is recalcitrant to standard medical management”. Thus, the increased awareness, research and development for chronic disorders will lead to the growth of the market within the forecast period, whereas, lack of skilled professionals with no proper line of treatment for the disease in the market could hamper the market growth.
North-America Got Significant Share
Chronic Pancreatitis Market Regional Analysis
The chronic Pancreatitis market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. According to the World Health Organization, around 4,95,773 patients were diagnosed with pancreatic cancer around the globe in 2020. As per an article published by the National Library of Medicine, chronic alcohol use, one of the common causes of gallstones, accounted for 17% to 25% of cases of the condition globally, in 2022. The North America Chronic Pancreatitis market is expected to dominate the market over the forecast period, majorly because of the highly developed healthcare systems, and increasing alcohol consumption in the United States and Canada. Europe is anticipated to see growth in the chronic pancreatitis market owing to the changing unhealthy lifestyle, and eating habits of the population in countries such as the UK and Germany. The Asia Pacific region is also expected to cover a large market share due to the growing population in the region.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The chronic pancreatitis market report provides granular level information about the market size, regional market share, historic market (2019-2023) and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Chronic Pancreatitis Market Segmentation
By Treatment
By Causes
- Damaged Pancreatic Duct
- Cancer
- Auto-Immune Disorder
- Cystic Fibrosis
- Gall Stones
- Hereditary
- Others
By Diagnosis
- CT Scan
- Magnetic Resonance Cholangiopancreatography
- Ultrasound Sonography
- Others
By Route of Administration
- Oral
- Parenteral
By End User
- Hospitals
- Homecare
- Others
Frequently Asked Questions
The Chronic Pancreatitis market was valued at USD 8.2 billion in 2022 and is expected to grow at a 5.7% CAGR over the forecast period 2023 – 2029.
Technological advancements and increasing healthcare expenditure are the key opportunities for the Chronic Pancreatitis market.
An increase in consumption of alcohol and a rise in unhealthy lifestyles are the growth drivers in the Chronic Pancreatitis market.
Kangen Pharma, AzurRX BioPharma, Theraly Fibrosis, First Wave BioPharma., Pfizer Inc., Baxter, B Braun, Hoffmann-La Roche Ltd., and Merck & Co., Inc. are a few companies operating in the Chronic Pancreatitis market.
| 1.Executive Summary |
| 2.Global Chronic Pancreatitis Market Introduction |
| 2.1.Global Chronic Pancreatitis Market - Taxonomy |
| 2.2.Global Chronic Pancreatitis Market - Definitions |
| 2.2.1.Treatment |
| 2.2.2.Causes |
| 2.2.3.Diagnosis |
| 2.2.0.Route of Administration |
| 2.2.1.Region |
| 3.Global Chronic Pancreatitis Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Chronic Pancreatitis Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Chronic Pancreatitis Market By Treatment, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Analgesic |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Artificial Digestive Enzyme |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Protein Supplements |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Steroids |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Antibiotics |
| 5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 5.6. Others |
| 5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.6.3. Market Opportunity Analysis |
| 6.Global Chronic Pancreatitis Market By Causes, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Damaged Pancreatic Duct |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Cancer |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Auto-Immune Disorder |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Cystic Fibrosis |
| 6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Gall Stones |
| 6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 6.6. Hereditary |
| 6.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.6.3. Market Opportunity Analysis |
| 6.7. Others |
| 6.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.7.3. Market Opportunity Analysis |
| 7.Global Chronic Pancreatitis Market By Diagnosis, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. CT Scan |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Magnetic Resonance Cholangiopancreatography |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Ultrasound Sonography |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Others |
| 7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 8.Global Chronic Pancreatitis Market By Route of Administration, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. Oral |
| 8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Parenteral |
| 8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 9.Global Chronic Pancreatitis Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. North America |
| 9.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.1.3. Market Opportunity Analysis |
| 9.2. Europe |
| 9.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.2.3. Market Opportunity Analysis |
| 9.3. Asia Pacific (APAC) |
| 9.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.3.3. Market Opportunity Analysis |
| 9.4. Middle East and Africa (MEA) |
| 9.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.4.3. Market Opportunity Analysis |
| 9.5. Latin America |
| 9.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.5.3. Market Opportunity Analysis |
| 10.North America Chronic Pancreatitis Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Treatment Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Analgesic |
| 10.1.2.Artificial Digestive Enzyme |
| 10.1.3.Protein Supplements |
| 10.1.4.Steroids |
| 10.1.5.Antibiotics |
| 10.1.6.Others |
| 10.2. Causes Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Damaged Pancreatic Duct |
| 10.2.2.Cancer |
| 10.2.3.Auto-Immune Disorder |
| 10.2.4.Cystic Fibrosis |
| 10.2.5.Gall Stones |
| 10.2.6.Hereditary |
| 10.2.7.Others |
| 10.3. Diagnosis Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.CT Scan |
| 10.3.2.Magnetic Resonance Cholangiopancreatography |
| 10.3.3.Ultrasound Sonography |
| 10.3.4.Others |
| 10.4. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Oral |
| 10.4.2.Parenteral |
| 10.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.5.1.United States of America (USA) |
| 10.5.2.Canada |
| 11.Europe Chronic Pancreatitis Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Analgesic |
| 11.1.2.Artificial Digestive Enzyme |
| 11.1.3.Protein Supplements |
| 11.1.4.Steroids |
| 11.1.5.Antibiotics |
| 11.1.6.Others |
| 11.2. Causes Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Damaged Pancreatic Duct |
| 11.2.2.Cancer |
| 11.2.3.Auto-Immune Disorder |
| 11.2.4.Cystic Fibrosis |
| 11.2.5.Gall Stones |
| 11.2.6.Hereditary |
| 11.2.7.Others |
| 11.3. Diagnosis Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.CT Scan |
| 11.3.2.Magnetic Resonance Cholangiopancreatography |
| 11.3.3.Ultrasound Sonography |
| 11.3.4.Others |
| 11.4. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.Oral |
| 11.4.2.Parenteral |
| 11.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.5.1.Germany |
| 11.5.2.France |
| 11.5.3.Italy |
| 11.5.4.United Kingdom (UK) |
| 11.5.5.Spain |
| 12.Asia Pacific (APAC) Chronic Pancreatitis Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Analgesic |
| 12.1.2.Artificial Digestive Enzyme |
| 12.1.3.Protein Supplements |
| 12.1.4.Steroids |
| 12.1.5.Antibiotics |
| 12.1.6.Others |
| 12.2. Causes Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Damaged Pancreatic Duct |
| 12.2.2.Cancer |
| 12.2.3.Auto-Immune Disorder |
| 12.2.4.Cystic Fibrosis |
| 12.2.5.Gall Stones |
| 12.2.6.Hereditary |
| 12.2.7.Others |
| 12.3. Diagnosis Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.CT Scan |
| 12.3.2.Magnetic Resonance Cholangiopancreatography |
| 12.3.3.Ultrasound Sonography |
| 12.3.4.Others |
| 12.4. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.Oral |
| 12.4.2.Parenteral |
| 12.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.5.1.China |
| 12.5.2.India |
| 12.5.3.Australia and New Zealand (ANZ) |
| 12.5.4.Japan |
| 12.5.5.Rest of APAC |
| 13.Middle East and Africa (MEA) Chronic Pancreatitis Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 13.1. Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Analgesic |
| 13.1.2.Artificial Digestive Enzyme |
| 13.1.3.Protein Supplements |
| 13.1.4.Steroids |
| 13.1.5.Antibiotics |
| 13.1.6.Others |
| 13.2. Causes Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Damaged Pancreatic Duct |
| 13.2.2.Cancer |
| 13.2.3.Auto-Immune Disorder |
| 13.2.4.Cystic Fibrosis |
| 13.2.5.Gall Stones |
| 13.2.6.Hereditary |
| 13.2.7.Others |
| 13.3. Diagnosis Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.CT Scan |
| 13.3.2.Magnetic Resonance Cholangiopancreatography |
| 13.3.3.Ultrasound Sonography |
| 13.3.4.Others |
| 13.4. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Oral |
| 13.4.2.Parenteral |
| 13.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.5.1.GCC Countries |
| 13.5.2.South Africa |
| 13.5.3.Rest of MEA |
| 14.Latin America Chronic Pancreatitis Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 14.1. Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.1.1.Analgesic |
| 14.1.2.Artificial Digestive Enzyme |
| 14.1.3.Protein Supplements |
| 14.1.4.Steroids |
| 14.1.5.Antibiotics |
| 14.1.6.Others |
| 14.2. Causes Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.2.1.Damaged Pancreatic Duct |
| 14.2.2.Cancer |
| 14.2.3.Auto-Immune Disorder |
| 14.2.4.Cystic Fibrosis |
| 14.2.5.Gall Stones |
| 14.2.6.Hereditary |
| 14.2.7.Others |
| 14.3. Diagnosis Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.3.1.CT Scan |
| 14.3.2.Magnetic Resonance Cholangiopancreatography |
| 14.3.3.Ultrasound Sonography |
| 14.3.4.Others |
| 14.4. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.4.1.Oral |
| 14.4.2.Parenteral |
| 14.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.5.1.Brazil |
| 14.5.2.Mexico |
| 14.5.3.Rest of LA |
| 15. Competition Landscape |
| 15.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 15.2.1.Kangen Pharma |
| 15.2.2.AzurRX BioPharma |
| 15.2.3.Theraly Fibrosis |
| 15.2.4.First Wave BioPharma. |
| 15.2.5.Pfizer Inc. |
| 15.2.6.Baxter |
| 15.2.7.B Braun |
| 15.2.8.Hoffmann-La Roche Ltd. |
| 15.2.9.Merck & Co., Inc. |
| 15.2.10.GlaxoSmithKline plc. |
| 15.2.11.Sanofi |
| 16. Research Methodology |
| 17. Appendix and Abbreviations |
- Kangen Pharma
- AzurRX BioPharma
- Theraly Fibrosis
- First Wave BioPharma.
- Pfizer Inc.
- Baxter
- B Braun
- Hoffmann-La Roche Ltd.
- Merck & Co., Inc.
- GlaxoSmithKline plc.
- Sanofi